All News

The proportion of US women aged 21 to 29 years who have never received cervical cancer screening more than doubled between 2005 and 2023, according to new data.

Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.

Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.

FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.

FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.

Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.

Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.

Once-weekly insulin's longer half-life reshapes the hypoglycemia conversation, and trial data point to a bigger role for CGM in primary care.

FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.

FDA authorized Aletta, a robotic venous blood collection device for supervised outpatient use, through the De Novo pathway.

Josef Coresh, MD, discusses biomarkers, hearing correction, and integrated vascular care as emerging dementia prevention strategies.

FDA approved garetosmab for adults with FOP after phase 3 data showed fewer new HO lesions and clinician-assessed flare-ups vs placebo.

If approved, ecopipam would be the first new therapy indicated for pediatric patients with Tourette syndrome in more than 10 years.

A nurse practitioner discusses why once-weekly basal insulin matters, who benefits most, and how its starting doses differ from daily insulin.

Phase 3 LUCIDITY results showed avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% vs placebo in post-bariatric hypoglycemia.

The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.

Stepped reminders to PCPs and patients increased annual lung cancer screening adherence by 27.7 percentage points, according to new research.

Relationship-based navigation helped more primary care patients access health and social services than referral to a free information service.